Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia:a non-inferiority, open-label, multicentre, randomised trial

Autor: Nick A de Jonge, Jonne J Sikkens, Sonja Zweegman, Aart Beeker, Paula Ypma, Alexandra H Herbers, Wies Vasmel, Arne de Kreuk, Juleon L L M Coenen, Birgit Lissenberg-Witte, Mark H H Kramer, Michiel A van Agtmael, Jeroen J W M Janssen

Publikováno v: de Jonge, N A, Sikkens, J J, Zweegman, S, Beeker, A, Ypma, P, Herbers, A H, Vasmel, W, de Kreuk, A, Coenen, J L L M, Lissenberg-Witte, B, Kramer, M H H, van Agtmael, M A & Janssen, J J W M 2022, ' Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia : a non-inferiority, open-label, multicentre, randomised trial ', The Lancet Haematology, vol. 9, no. 8, pp. e563-e572 . https://doi.org/10.1016/S2352-3026(22)00145-4
The Lancet Haematology, 9(8), e563-e572. Lancet Publishing Group

Background: Early antibiotic discontinuation has been advocated in haematology patients with fever of unknown origin during chemotherapy-induced neutropenia, but its safety is unknown. We aimed to assess if short treatment with carbapenems is non-inf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3bc013d785bcdc51263bca9e1dc6cd
https://research.vumc.nl/en/publications/80a00e6d-2539-4cbd-a89e-588979fd5ba2

199. Short versus Extended Antibiotic Treatment with a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients with Fever of Unknown Origin: A Randomized Multicenter Noninferiority Trial

Autor: Sonja Zweegman, Jeroen Janssen, Juleon Coenen, Paula F. Ypma, Wies Vasmel, Birgit I. Lissenberg-Witte, Michiel A. van Agtmael, Andries E. Budding, Nick A. de Jonge, Jonne J. Sikkens, Arne M. De Kreuk, Aart Beeker, Alexandra H E Herbers, Mark H.H. Kramer

Publikováno v: Open Forum Infectious Diseases

Background In hematology patients with high risk neutropenia due to intensive chemotherapy the optimal antibiotic treatment duration for fever of unknown origin (FUO) is unknown. Early antibiotic discontinuation has been advocated to reduce unnecessa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f36443f3cb363c33b46c7528218df55
https://doi.org/10.1093/ofid/ofaa439.509